News
-
-
COMMUNIQUÉ DE PRESSE
BioNxt Announces Enhanced Sublingual Product Development Pipeline with Innovative Solutions for Autoimmune Diseases and Longevity
BioNxt Solutions Inc. expands next-gen product pipeline targeting autoimmune diseases & longevity market. Innovative drug delivery systems show promise in major high-growth markets -
-
-
COMMUNIQUÉ DE PRESSE
BioNxt Announces National Level Patent Filings for Sublingual Anticancer Drugs for the Treatment of Autoimmune Neurodegenerative Diseases
BioNxt Solutions Inc. initiates nationalization process for sublingual anticancer drug patents for autoimmune neurodegenerative diseases. Positive report from European Patent Office on patentability -
-
-
COMMUNIQUÉ DE PRESSE
Terry Lynch Joins BioNxt as Capital Markets Advisor
BioNxt Solutions Inc. appoints Terry Lynch, a capital markets advisor with extensive experience in resource and bioscience sectors. Mr. Lynch joins the team to support the development and commercialization of the sublingual Cladribine product for MS treatment -
-